Human TAFA2/FAM19A2 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB4179
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Ala31-His131
Accession # AAH28403
Specificity
Clonality
Host
Isotype
Applications for Human TAFA2/FAM19A2 Antibody
Western Blot
Sample: Recombinant Human TAFA2/FAM19A2 (Catalog # 4179-TA)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TAFA2/FAM19A2
TAFA2, also called FAM19A2, is a secreted, 11 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 131 amino acid (aa) precursor that contains a 30 aa signal sequence and a 101 aa mature chain . Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, where C represents a conserved cysteine residue and X represents any noncysteine amino acid (1). Human TAFA2 shares 97% aa sequence identity with mouse TAFA2 (1). TAFA2 expression can be detected in the central nervous system (CNS), colon, heart, lung, spleen, kidney, and thymus, but its expression in the CNS is 50- to 1000-fold higher than in other tissues (1). Within the CNS, TAFA2 expression is highest in the occipital and frontal cortex (3- to 10-fold more abundantly expressed than in other cortical regions) and medulla (1). Hypotheses for the biological functions of TAFA family members include modulating immune responses in the CNS by functioning as brain-specific chemokines, acting with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Alternately, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1 - 2). Finally, TAFAs may control axonal sprouting following brain injury (1).
References
- Tang, Y.T. et al. (2004) Genomics 83:727.
- Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional TAFA2/FAM19A2 Products
Product Documents for Human TAFA2/FAM19A2 Antibody
Product Specific Notices for Human TAFA2/FAM19A2 Antibody
For research use only